Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 18/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30111763 | 0.80 | BRD4 (0.41) | NOTUMKMT2A | |
| SCHEMBL24034889 | 0.80 | BRD4 (0.41) | NOTUMKMT2A | |
| SCHEMBL30111768 | 0.80 | BRD4 (0.41) | NOTUMKMT2A | |
| SCHEMBL12530244 | 0.78 | KMT2A (0.50) | KCNN4HPGDKMT2A | |
| SCHEMBL29848689 | 0.78 | NOTUM (0.51) | KCNN4NOTUM | |
| SCHEMBL2683661 | 0.74 | PTGS2 (0.49) | NOTUM | |
| SCHEMBL9895165 | 0.74 | NPSR1 (0.45) | KCNN4NOTUMHPGDKMT2A | |
| SCHEMBL9894573 | 0.73 | KCNN4 (0.41) | KCNN4NOTUMHPGDKMT2A | |
| SCHEMBL2687662 | 0.72 | KCNN4 (0.49) | KCNN4HPGDKMT2A | |
| SCHEMBL2217305 | 0.71 | HTT (0.46) | KCNN4NOTUMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2638029-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062687-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | GABRA5, GABRA3, GABRA1 | KCNN4 957/4885NOTUM 2314/4885HPGD 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.